Latest progress
Recently, Salubris has received the acceptance notice issued by NMPA accepting the application for clinical trial of SAL008 injection, a self-developed innovative first-in-class anti-tumor biological drug with intellectual property.
SAL008 (JK08), a fusion protein of IL-15/IL-15Rα complex and anti-CTLA-4 antibody, was independently developed by SalubrisBio, a subsidiary of Salubris, for the treatment of advanced solid tumors.
Previously, JK08 started a phase I clinical study after submitting a CTA (European Application for Clinical Trials) in Europe, and recruiting is ongoing now.
Basic Information
Drug name: SAL008 injection
Registry Classification: 1 category
Application information: Registered clinical trials of domestic manufactured drugs
Acceptance number: CXSL2200503
Acceptance instructions: According to the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China, it is decided to accept it after examination.
